Mar 12, 2026 4:05 pm EDT Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Mar 09, 2026 4:30 pm EDT Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
Mar 09, 2026 8:00 am EDT Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
Feb 26, 2026 4:05 pm EST Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Feb 11, 2026 7:00 pm EST Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Jan 06, 2026 8:00 am EST Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Dec 12, 2025 11:00 am EST Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Nov 26, 2025 4:05 pm EST Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2025 4:05 pm EST Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 07, 2025 6:10 pm EST Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
